Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in Acute Coronary Syndrome: The Randomized TIDES-ACS Trial
Pim A L Tonino, Nico H J Pijls, Carlos Collet, Wail Nammas, Jan Van der Heyden, Hannu Romppanen, Kari Kervinen, Juhani K E Airaksinen, Jussi Sia, Jacques Lalmand, Peter Frambach, Antonio Serra Penaranda, Bernard De Bruyne, Pasi P Karjalainen, TIDES-ACS Study Group, Pim A L Tonino, Nico H J Pijls, Carlos Collet, Wail Nammas, Jan Van der Heyden, Hannu Romppanen, Kari Kervinen, Juhani K E Airaksinen, Jussi Sia, Jacques Lalmand, Peter Frambach, Antonio Serra Penaranda, Bernard De Bruyne, Pasi P Karjalainen, TIDES-ACS Study Group
Abstract
Objectives: This study sought to compare next-generation cobalt-chromium-based titanium-nitride-oxide (TiNO)-coated stents with a platinum-chromium-based biodegradable polymer everolimus-eluting stent (EES) in patients with acute coronary syndrome (ACS).
Background: Previous generation TiNO-coated stents showed acceptable performance in patients with ACS.
Methods: In a multicenter, randomized trial, we randomly assigned 1,491 ACS patients (2:1) to receive either a TiNO-coated stent (n = 989) or EES (n = 502). The primary endpoint was the rate of a composite of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization at 12-month follow-up. The co-primary endpoint was a composite of cardiac death, MI, or major bleeding at 18 months.
Results: A primary endpoint event occurred in 6.3% of patients in the TiNO-coated stent group versus in 7.0% in the EES group (hazard ratio: 0.93; 95% confidence interval: 0.71 to 1.22; p = 0.66 for superiority; p < 0.001 for noninferiority). A co-primary endpoint event occurred in 3.7% of the patients in the TiNO group and in 7.8% in the EES group (hazard ratio: 0.64; 95% confidence interval: 0.51 to 0.80; p = 0.001). TiNO-coated stents were associated with lower rates of cardiac death (0.6% vs. 2.6%; p = 0.002) and MI (2.2% vs. 5.0%; p = 0.007) at 18 months of follow-up. Rates of target lesion revascularization were not significantly different at 18 months (5.8% vs. 4.4%; p = 0.27).
Conclusions: In patients with ACS, cobalt-chromium-based TiNO-coated stents were noninferior to platinum-chromium-based biodegradable polymer EES for major cardiac events at 12 months, and were superior for the co-primary endpoint of cardiac death, MI, and bleeding at 18 months. (Comparison of Titanium-Nitride-Oxide-Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome [TIDES-ACS]; NCT02049229).
Keywords: acute coronary syndrome; drug-eluting stent; everolimus-eluting stent; stent thrombosis; titanium-nitride-oxide–coated stent.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed